Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New pill for fatty liver disease enters first human tests
Disease control OngoingThis early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive …
Phase: PHASE1 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for rare liver disease: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests an experimental drug called CS0159 in 50 people with primary sclerosing cholangitis (PSC), a rare liver disease. The study has a 12-week placebo-controlled phase followed by a 40-week open-label period to check safety and how well the drug works. Research…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC